Results 21 to 30 of about 89,590 (297)
Kidney & Blood Pressure Research, 2013 Background: Treating non-diabetic proteinuric patients with advanced renal disease with an angiotensin-converting enzyme (ACE) inhibitor is still subject to discussion.
Charles Christian Adarkwah +3 more
doaj +1 more source
Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis [PDF]
The Korean Journal of Internal Medicine, 2021 Background/Aims Inhibitors of the renin-angiotensin system, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), reportedly have anti-inflammatory effects.
Hyun Woo Lee +3 more
doaj +1 more source
Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes [PDF]
, 1994 Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Anaphylactoid reactions (AR) are the most feared complications of hemodialysis.
Verresen, Luc +3 more
core +1 more source
Dose response of ACE inhibitors: implications of the SECURE trial
Current Controlled Trials in Cardiovascular Medicine, 2001 The choice of the appropriate dosage of ACE inhibitor in clinical practice is an important one. The available evidence suggests that in chronic heart failure as well as in chronic coronary artery disease, high doses of angiotensin-converting enzyme (ACE)
Lonn Eva
doaj +1 more source
The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans [PDF]
, 2012 Aims - Inhibition of neutral endopeptidases (NEP) results in a beneficial increase in plasma concentrations of natriuretic peptides such as ANP.
Johnston, F. +26 more
core +1 more source
Folia Medica Indonesiana, 2017 BNP secreted by left ventricle as response to wall stress in patient with heart failure. Elevated concentration of NT-pro-BNP correlate with severity of heart failure across all stages of the condition and left ventricle ejection fraction in patient ...
Halla Hisan Hartoto +2 more
doaj +1 more source
Effect of angiotensin‐converting enzyme inhibition on cardiovascular adaptation to exercise training
Physiological Reports, 2022 Angiotensin‐converting enzyme (ACE) activity may be one determinant of adaptability to exercise training, but well‐controlled studies in humans without confounding conditions are lacking.
Tórur Sjúrðarson +13 more
doaj +1 more source
Therapeutic approaches to slowing the progression of diabetic nephropathy – is less best?
Drugs in Context, 2013 Objective: Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors are known to reduce proteinuria and have been the first-line agents in the management of diabetic nephropathy for the past 20 years.
Eva Vivian, Chelsea Mannebach
doaj +1 more source
ACE Inhibitors and Chronotherapy
Clinical and Experimental Hypertension, 2005 Chronotherapy can improve the effectiveness and reduce the adverse reactions of drugs and actually is used for several conditions including cardiovascular diseases. Although angiotensin converting enzyme (ACE) inhibitors are available for the therapy of patients with hypertension and/or heart failure, these agents have some characteristic adverse ...
Masami, Ohmori, Akio, Fujimura
openaire +2 more sources
Circulation, 1998 To the Editor: In a recent issue of Circulation , Brown and Vaughan1 reviewed ACE inhibitors. They stated that captopril and lisinopril are active drugs and listed 7 other ACE inhibitors approved in the United States that are inactive prodrugs until metabolized in the liver.
openaire +2 more sources